Cargando…
Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
INTRODUCTION: It is uncertain if the combination of sodium‐glucose co‐transporter 2 inhibitors (SGLT2‐Is) and renin‐angiotensin‐aldosterone system inhibitors (RAAS‐Is) provides better cardio‐renal clinical outcomes in people with type 2 diabetes mellitus (T2DM) compared with SGLT2‐Is alone. Using a...
Autores principales: | Seidu, Samuel, Kunutsor, Setor K, Topsever, Pinar, Khunti, Kamlesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754244/ https://www.ncbi.nlm.nih.gov/pubmed/34636161 http://dx.doi.org/10.1002/edm2.303 |
Ejemplares similares
-
Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021) -
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
por: Koutentakis, Michail, et al.
Publicado: (2023) -
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023) -
Precipitation of Euglycemic DKA (euDKA) From the Initiation of SGLT2 Inhibitor (SGLT2i) and 0-Carb Diet Inpatient
por: Popli, Rakesh, et al.
Publicado: (2021) -
ODP054 The Impact of SGLT2-inhibitors on Renin-Aldosterone axis and Adrenal Incidentaloma's work up: Case study and literature review
por: Alkhaddo, Jamil, et al.
Publicado: (2022)